The role of the hedgehog (Hh) signaling pathway has been well documented in vertebrate embryonic development, stem cell maintenance, and tumorigenesis (reviewed in references 8 and 9). Activation of the Hh signaling is a driving force in the development of both hereditary and sporadic cases of BCC. These tumors are the most common of all skin cancers, with an estimated 1 million new cases per year in the United States alone.¹⁰ Each of the three Hh genes—Sonic hedgehog (SHH), Desert hedgehog (DHH), Indian hedgehog (IHH)—encodes a secreted signaling peptide that binds to a membrane bound 12-span transmembrane receptor called Patched (PTCH1 or PTCH2). Binding of Hh ligand to the PTCH receptor on the target cell alleviates PTCH-mediated suppression of the 7-span transmembrane protein called Smoothened (SMO). SMO activation initiates an intracellular signal transduction cascade that ultimately activates the expression of Hh target genes. Transcriptional activation of Hh target genes in mammals occurs through the actions of three related proteins: GLI1, GLI2, and GLI3.^11,12 GLI3 acts primarily as a transcriptional repressor,¹³ whereas GLI2 is reported to be the primary activator of Hh signaling, and GLI1 is a secondary target, downstream of GLI2, that also acts as a transcriptional activator.¹⁴

Aberrant regulation of the Hh pathway contributes to the development of many human cancers. Activating mutations of SMO or suppressing mutations of PTCH have been shown to constitutively activate the Hh signaling pathway (reviewed in reference 15). Involvement in human BCC was found through analysis of nevoid BCC kindreds (Gorlin syndrome, basal cell nevus syndrome).¹⁶ Persons with this autosomal dominant disease have odontogenic cysts, skeletal defects, palmar pits, various associated visceral tumors (medulloblastoma, meningioma, fibrosarcoma, cardiac fibroma, and ovarian fibroma), and multiple BCCs by a median age of 20 years. Early analyses mapped the defect to a tumor suppressor gene on chromosome 9q22–q31.¹⁷ This site proved to be the location of the PTCH1 gene. It was later elucidated that patients with nevoid BCC syndrome inherit one defective chromosome 9q region with loss of heterozygosity in the PTCH1 locus. Many BCCs from these patients show inactivation of the remaining PTCH1 gene through acquired somatic mutations, consistent with the view that the BCC phenotype develops once both alleles are nonfunctional. Thus, PTCH1 acts as a classic tumor suppressor gene in the skin. Mutations in PTCH1 also are common in many sporadic BCCs, as are mutations in other Hh pathway genes, including SMO, PTCH2, and SHH (reviewed in reference 18).

Epidemiology

BCC accounts for approximately 80% of all skin cancers. The American Cancer Society reports more than 2 million cases of BCC and SCC yearly in the United States. Worldwide, the incidence for BCC varies widely, with the highest rates in Australia (>1000/100,000 person-years) and the lowest rates in parts of Africa (<1/100,000 person-years).⁴⁸ In Australia, the annual incidence of BCC is slightly over 2% in males and 1% to 1.5% in females, while that of SCC is approximately 1% in males, and 0.5% to 0.8% in females (calculated from “Table 70-1. Age-Standardized Rates of NMSC in Whites per 100,000 Population from Australia, United States, and Europe [Selected Studies after 1990]” in reference 49).⁴⁹ The incidence of BCC has increased over the past decades in a manner similar to the increase in melanoma. It is estimated that the incidence of NMSC is increasing 2% to 3% yearly.⁵⁰ One study, conducted in New Hampshire, showed an annual increase in the incidence of SCC of approximately 10% and of BCC of approximately 5%.⁵¹

Etiology and Biological Characteristics

Exposure to ultraviolet radiation is the major risk factor for the development of BCC, especially severe sunburn during childhood and adolescence.⁵² Interestingly, the risk of BCC is significantly increased by recreational, intermittent intense exposure to the sun, whereas SCC appears to be strongly related to cumulative sun exposure.^54–54 Other associated risk factors are Fitzpatrick skin types 1 and 2, red hair, freckling in childhood, family history of skin cancer, male sex, and Celtic ancestry.⁵⁵ BCC is more common in lighter skinned African Americans than in darker persons.⁵⁶ Immunodeficiency secondary to acquired immunodeficiency syndrome or organ transplantation also is associated with increased risk of BCC.^57,58 Other uncommon risk factors include exposure to arsenic,⁵⁹ oral methoxsalen (psoralen) and UVA radiation,⁶⁰ and ionizing radiation,⁶¹ especially among patients who have received radiation for acne.

Keratin pattern and immunohistochemical results suggest the origin of BCC is the outer root sheath of the hair follicle below the isthmus.⁶² Recent work using genetic mouse models of BCC has shown that stem and progenitor cells are the most probable sources of BCC initiation.⁶³ The locally invasive characteristic of BCC could be related to the presence of an abnormal hemidesmosome-anchoring fibril complex.⁶⁴ Genetic abnormalities and mutations are thought to play a major role in development of BCC, especially in inherited syndromes of BCC. Patients with XP cannot repair the UV-induced DNA mutations; therefore, they are at increased risk of cutaneous carcinogenesis. Mutations in the Hh signaling pathway genes and TP53 are important in the pathogenesis of sporadic BCC and those arising in patients with the basal cell nevus syndrome (BCNS) and XP.^20,65–68

Prevention and Early Detection

Patients need to be educated on self-skin examination and about protection against sun exposure. Photoprotection is essential to prevent NMSCs,⁶⁹ and should begin at a young age to reduce the cumulative damage induced by the sun. Recently, chemopreventive agents for BCC have been explored, including retinoids,⁷⁰ nonsteroidal antiinflammatory drugs,^71,72 and difluoromethylornithine.⁷³ Targeted skin-cancer screening of high risk populations is effective for early detection of BCC.⁷⁴

Pathology and Pathways of Spread

In common nodular BCC, nodular masses of basaloid cells extend from the epidermis or outer root sheath into the dermis with surrounding connective tissue stroma (Fig. 70-1). A palisade arrangement of cells is present in the periphery. Sometimes as a result of tumor necrosis and disintegration, cystic spaces form. The surrounding stroma may retract from the tumor mass forming the typical lacunae, a sign that aids in diagnosis. In the pigmented type of BCC, large amounts of melanin are produced in the melanocytes that colonize the tumor. The many melanophages in the surrounding stroma also contribute to pigmentation. The superficial type of BCC shows multifocal small nests of basaloid tumor cells budding off the epidermis and adnexa. Morpheaform BCC is different in that strands of tumor cells are embedded in a dense fibrous tissue stroma. These strands often extend into the deeper dermis. Micronodular BCCs contain small nodules of tumor cells that invade surrounding stroma. The morpheaform and micronodular types are generally the most locally invasive variants of BCC. It is common for BCCs to show mixed histologic patterns of these various types. Even the less-invasive variants may invade deeply when located in regions of embryonic fusion planes, such as around the nose and ears.

Clinical Manifestations/Patient Evaluation/Staging

The most common location for BCC is the head and neck, especially the nose. BCC occurs on hair-bearing skin; mucosal surfaces are not involved. The major types of BCC include nodular, pigmented, superficial, and morpheaform. The typical nodular BCC is a dome-shaped, pearly papule with a telangiectatic surface and translucent rolled borders (Fig. 70-2). The surface might become ulcerated (Fig. 70-3). In darker-skinned individuals, especially African Americans, the more darkly pigmented BCCs may be misdiagnosed as seborrheic keratosis or nodular melanoma. Superficial BCC is a well-demarcated erythematous scaly plaque with elevated borders that often occurs on the trunk or extremities. It might be confused with Bowen disease or nummular eczema. The most difficult BCC to diagnose and manage is the morpheaform or sclerosing variant. This ill-defined, white, indurated plaque can be mistaken for a scar or localized patch of scleroderma, and therefore is ignored by patient and physician, with resulting wide subclinical extension.

Patients with lesions clinically suspicious for BCC should undergo skin biopsy for histologic evaluation. Pertinent history is taken, such as the rate of growth, prior therapy, local neurologic symptoms, and evidence of immunosuppression, and a thorough skin examination is recommended. No formal staging system has been developed specifically for BCC, as metastasis of BCC is rare, with rates ranging from 0.003% to 0.55%.⁷⁵ The American Joint Committee on Cancer (AJCC) staging system for non-eyelid skin cancer (Table 70-1) can be used for BCC as well as SCC. Regardless, it is important to stratify BCC into high-risk or low-risk lesions to guide treatment. Criteria for high-risk BCC include size greater than 2 cm, location in the midface (H zone) or ear, morpheaform or other aggressive histologic pattern, long duration, incomplete excision, perineural or perivascular involvement, and recurrent lesion.⁷⁶

Two-thirds of BCC recurrences occur during the first 3 years after treatment.⁷⁷ The risk of development of another BCC is approximately 45% within 5 years.⁷⁸ The risk of development of another NMSC is associated with the number of previous NMSCs. In an Australian study of patients with three to nine previous NMSCs, the risk of development of a new cancer was 93%.⁷⁹ Patients treated for BCC need to be examined at least once a year for the first few years, preferably for 5 years after the last cancer was diagnosed. For patients with a history of multiple skin cancers, more frequent followup examinations are recommended.

Primary Therapy

BCC is rarely metastatic but can be locally invasive (Fig. 70-4). Consequently, eradicating the primary tumor is the goal of therapy. Several treatment options are available, both surgical and nonsurgical. Selection depends on the tumor type, patient profile, size and location of tumor, recurrence, physician’s experience, and patient preference. Surgical modalities include Mohs micrographic surgery, surgical excision, cryosurgery, and electrodessication and curettage (EDC). Nonsurgical options include radiation therapy and photodynamic therapy.^82–82 Other treatment modalities, such as immunotherapy with intralesional interferon⁸³ and topical 5% imiquimod (Aldara),⁸⁴ chemotherapy with 5-fluorouracil,⁸⁵ and retinoids,⁸⁶ have been reported with variable success (Fig. 70-5).

A systematic review of studies in which investigators reported recurrence rates of BCC after different treatment modalities showed that the mean 5-year recurrence rates after Mohs surgery and surgical excision were approximately 1% and 5.3%, respectively.⁸⁷ High-risk BCC with increased risk for recurrence should be completely resected, preferably by Mohs technique or excision with margin control. Mohs surgery should be used in areas where preserving maximum tissue is important, such as eyelids, nose, and lips. It is also indicated for recurrent BCC and tumors with ill-defined clinical margins. The American Academy of Dermatology (AAD) has developed its first appropriate use criteria (AUC) on Mohs micrographic surgery in collaboration with the American College of Mohs Surgery (ACMS), American Society for Mohs Surgery (ASMS), and American Society for Dermatologic Surgery (ASDS). The Mohs AUC was recently published in journal of the American Academy of Dermatology⁸⁸ and Dermatologic Surgery.⁸⁹ If simple excision is used, the margin for excision, according to the newest National Comprehensive Cancer Network (NCCN) guidelines, should be at least 4 mm for low-risk tumors, and 10 mm for high-risk tumors. If there are contraindications to surgery, or a low-risk tumor that is small and located on less-critical sites, such as the trunk, cryotherapy or EDC can be used with good outcome. Because of the less-favorable long-term cosmetic results and the possibility of secondary radiation-induced skin cancer, radiation therapy is best avoided in the care of relatively young patients.

Treatment of Locally Advanced and Metastatic Disease

Very large or poorly controlled BCC may necessitate a coordinated approach of standard surgical excision, Mohs surgery, radiation therapy, and immunotherapy or chemotherapy.⁹⁰ Targeted therapy suppressing the Hh signaling pathway at the level of SMO, or at the final effectors, GLI transcription factors, has been proven effective. GDC-0449 (Vismodegib), a synthetic oral inhibitor of SMO, is the first FDA-approved drug in this category. GDC-0449 is indicated for adults with metastatic BCC, or with locally advanced BCC that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.^63,91

Controversies/Problems/Challenges/Future Possibilities and Clinical Trials

Other potential new BCC therapies include vitamin D₃, which works through blocking Hh signaling, topical treatment with the RARB/RARG-selective retinoid, tazarotene,⁶³ and molecules targeting epidermal growth factor receptor (EGFR) pathway.⁹² It remains to be determined whether the strategy of inhibiting Hh signaling will truly result in the eradication of BCC and why certain tumors are refractory to such treatment.⁶³

Epidemiology

SCC is the second most common skin cancer in the United States, representing approximately 20% of NMSCs. Interestingly, SCC occurs more than BCC in blacks and Asians.⁹³ It is more common in men than women.¹⁰

Etiology and Biological Characteristics

There are many risk factors for SCC, the most important being solar radiation. The incidence of SCC is increasing especially on the head and neck area as a result of exposure to sunlight.⁹⁴ SCC is thought to be correlated with recent (in the 10 years preceding diagnosis) chronic sunlight exposure⁹⁵ and cumulative sun exposure.⁹⁶ Phototherapy with PUVA (psoralen + ultraviolet A) increases the risk of SCC. Other risk factors for SCC include fair skin, red hair, albinism, and Celtic origin. Nonsolar risk factors include exposure to chemicals (insecticides and herbicides),⁹⁷ arsenic, organic hydrocarbons, chronic thermal injury and scars, ionizing radiation, and chronic immunosuppression.⁹⁸ The incidence of SCC is increased by 65 times in organ transplant patients, as compared to the tenfold increase of BCC.⁹⁹ This increase of risk is correlated with the type of organ transplantation and elapsed time after transplantation. Heart and lung transplant recipients have a higher risk of NMSC than kidney transplant recipients, possibly because of more intense immunosuppression.^99,100 SCCs in organ transplant patients are usually more aggressive, with an increased risk of metastases of approximately 8%, as compared to the risk of 0.5% to 5% in the general population.¹⁰¹ Tobacco is a risk factor for oral SCC. Viruses, especially human papillomavirus (HPV), have been linked to epithelial malignancies, including SCC. This is especially true among patients with epidermodysplasia verruciformis, who have an underlying immunodeficiency and can develop SCCs within HPV-infected warts.⁹⁸

Carcinogens, such as ultraviolet radiation (UVR), certain chemicals, and viruses play a role in the pathogenesis of SCC by damaging keratinocyte DNA and other cellular contents. It is known that UVR, especially UVB, causes mutations in DNA of keratinocytes.¹⁰² Early repair of these mutations is important for the prevention of SCC. Patients with NMSC are thought to have decreased ability for DNA repair compared with controls, thus making them more susceptible to the effects of UVR.¹⁰³ One example is the effect of UVR on DNA alterations in patients with XP who are genetically unable to repair these defects. UVR also causes cutaneous immunosuppression, weakening the host’s immune response against tumor cells and promoting tumor growth.¹⁰⁴ Studies of SCCs have shown that mutations in the TP53 tumor suppressor gene are an early event.^3,105 Most of the mutations occur at dipyrimidine sequences, in the form of UV-induced cyclobutane pyrimidine dimers.¹⁰⁶ The development of SCC does not occur by a simple single step, but rather through a multistage process. Conversion of susceptible keratinocytes to premalignant cells and then progression to carcinoma occurs as a result of successive genetic hits.¹⁰⁷ In the initiation stage of carcinogenesis, there is clonal expansion of premalignant cells. The next stage is increased proliferation of premalignant cells and subsequent chromosomal aberrations. The final stage is conversion to SCC. DNA aneuploidy with a single peak was detected by flow cytometry in lesions of Bowen disease, suggesting a monoclonal proliferation of abnormal keratinocytes and a clonal basis for skin cancer.¹⁰⁸ Aberrant expression of P-cadherin, and changes in expressions of cytokeratins and transforming growth factors, all play a role in tumor progression.¹⁰⁹

Prevention and Early Detection

Prevention of SCC is similar to that of BCC, that is, an emphasis on photoprotection is essential. Interestingly, one study showed that regular application of sunscreen has prolonged preventive effects on SCC but with no statistically significant benefit in reducing BCC.¹¹⁰ Treatment of precursor actinic keratoses with field therapy such as photodynamic therapy, topical 5- fluorouracil and imiquimod cream may reduce the number of lesions transformed into SCC. Promising chemopreventive agents for lesions in the actinic keratosis–SCC spectrum include retinoids, cyclooxygenase (COX)-2 inhibitors, difluoromethylornithine, and epigallocatechin gallate (EGCG), a green tea catechin.¹¹¹ In organ transplant recipients, systemic retinoids and reduction of immunosuppression are used as preventative means in reducing the incidence of NMSCs.¹⁰⁰ One study showed that high-dose topical tretinoin, however, is ineffective at reducing risk of NMSCs in high-risk patients.⁷⁰

Pathology and Pathways of Spread

A deep shave or punch biopsy that includes the base of the tumor is needed to distinguish SCC in situ from invasive SCC. Bowen disease is SCC in situ. The stratum corneum is thickened, and epidermis is hyperplastic with disordered maturation of keratinocytes. Mitotic figures, multinucleated keratinocytes, and dyskeratotic cells with hyperchromatic nuclei and eosinophilic cytoplasm are seen in the epidermis. Atypical cells can invade follicular and ductal structures. The histology of invasive SCC shows masses of epidermal cells proliferating into the dermis. Atypical squamous cells and mitotic figures are seen (Fig. 70-6). The cells have abundant eosinophilic cytoplasm and large nuclei. Horn pearls, which are a result of keratinization of squamous cells, are seen. The dermis may show a marked inflammatory reaction. Spindle cell SCC is a rare variant composed of mainly spindle cells, but some squamous differentiation may be seen. Spindle cells have large vesicular nuclei and scant cytoplasm and intermingle with the collagenous stroma. Spindle cell SCC is poorly differentiated with numerous mitoses and deep invasion and requires immunohistochemistry to differentiate it from other spindle cell tumors. Another uncommon histologic variant of SCC is the acantholytic or adenoid SCC, seen more on the face and neck. There are nests of tumor cells with dyskeratotic cells and central acantholysis forming pseudoglandular structures.

Clinical Manifestations/Patient Evaluation/Staging

SCC occurs more on the head and neck area in whites, but in blacks there is no predilection for sun-exposed areas of the body.¹¹² SCC in situ can arise de novo or from premalignant lesions, such as actinic keratosis or arsenical keratosis. In fact, in whites, the majority of SCCs arise from actinic keratoses. These can eventually spread beyond the epidermis and become invasive. Bowen disease is a SCC in situ arising de novo. If Bowen disease occurs on the glans penis or rarely vulva it is referred as erythroplasia of Queyrat. Bowen disease often appears as a well-defined single red plaque with dry surface scaling. Lesions are slow growing and asymptomatic, thus ignored by many patients. The physician might initially treat it as psoriasis or nummular eczema with no response. There is a 3% to 5% chance that Bowen disease can progress into invasive SCC.¹¹³ Clinically erythroplasia of Queyrat resembles Bowen disease, but lacks the dry superficial scale. Instead, the surface is moist and smooth.

Invasive SCC can also arise from normal skin. It starts as a small, firm, dull-red nodule, which can undergo central ulceration. Sometimes if SCC arises from solar keratosis an adherent keratotic scale can be seen. If ignored, the lesion grows horizontally and vertically and may become fixed to the underlying tissue. The surface might become ulcerated with bleeding, malodorous exudate, or crust. The borders are usually elevated and firm. Occasionally a fungoid lesion without ulceration can be seen. SCC of the lower lip often arises from previously solar-damaged areas (actinic cheilitis). Initially local thickening of the vermilion border occurs that then progresses into a noduloulcerative lesion (Fig. 70-7). Persistent subungual erythema with pain and swelling should alert the physician for SCC of the nail region. This form of SCC may be confused with warts (Fig. 70-8). As mentioned earlier, SCCs can arise from chronic sinuses, scars, and chronic thermal damage.

Verrucous carcinoma is a distinct slow-growing low-grade type of SCC. The most common location is the plantar foot (epithelioma cuniculatum), but it can occur on the buttocks, genitals (giant condyloma of Buschke and Löwenstein), face, oral cavity (oral florid papillomatosis), trunk, nails, and extremities. It grows as an exophytic verrucous mass. Clinically, on the foot it can be mistaken for a plantar wart. It is locally aggressive and may penetrate into deep soft tissue or bone.

The risk of metastasis of SCC is variable, depending on the site and tumor characteristics. The deeper and larger the tumor, the higher is the chance of metastasis. Recurrent tumors are at high risk for metastasis. Lesions with perineural involvement have a 35% metastatic rate.¹¹⁴ Among the different histologic types, desmoplastic SCCs are more likely to metastasize.¹¹⁵ The risk of metastasis of SCC derived from actinic keratosis is low (0.5% to 3.7%) compared with SCC arising in radiation-induced SCC and chronic osteomyelitis (20% and 31%, respectively).^118–118 High-risk areas for metastasis include tumors arising from the dorsal hands, lips, ears, and penis. For example, SCC of the lower lip has a 15% risk of metastasis.¹¹⁹ Bowen disease and erythroplasia of Queyrat have a low chance of metastasis, but once they become invasive, the risk of metastasis increases significantly.

Evaluation for patients with SCC is similar to that of BCC, and stratification of SCC into high-risk or low-risk tumors is practical to guide treatment. However, physicians must be reminded that SCCs in general have a greater potential for recurrence and metastasis than BCCs. The first step is to estimate the peripheral and vertical extension of tumor cells. The new seventh edition of the AJCC staging system for noneyelid skin cancer, including cutaneous SCC, incorporates tumor-specific (T) staging features, such as thickness greater than 2 mm, Clark level greater than IV, perineural invasion, anatomic site, and degree of histologic differentiation (see Table 70-1).^120,121 Other reported high-risk features that may result in local and distant metastasis are size greater than 2 cm, recurrent status, and immunocompromised host.¹²² Next, the patient should be evaluated for metastasis to the lymph nodes and other organs. Note that eyelid skin cancers are staged differently, using a separate system that is described in the section on sebaceous carcinoma. For SCC patients, closer followup intervals are recommended, such as every 3 to 6 months for the first several years, depending on the location, size, aggressiveness, and node status of the primary tumor. The exception would be small SCCs arising from actinic keratoses on sun-exposed surfaces, where the rate of metastasis is very small (0.5%). In these patients, routine followup every 6 to 12 months is all that is required.

Primary Therapy

The treatment options for SCC are similar to BCC treatment, with some differences (Fig. 70-9).

Destructive methods or surgical excision can treat Bowen disease effectively. When cancer cells invade hair follicles or ducts, treatment by excision is preferred. Small uncomplicated SCCs (<1 cm) in low-risk locations are frequently treated with EDC. Cryotherapy is an alternative treatment. Simple surgical excision with margin control is commonly used for smaller tumors and those on the trunk and extremities. According to the newest NCCN guidelines, the recommended margin for low-risk SCC is 4 to 6 mm, and for high-risk tumor is 10 mm, if possible.¹²³ The excision should include the subcutaneous fat. Mohs micrographic surgery is the treatment of choice for high-risk SCCs and for tissue preservation where tissue sparing is cosmetically or functionally vital.¹²⁴

Radiation can also be used as a primary choice of treatment in the elderly at high risk for surgical complications or patients with contraindications to anesthesia or surgery. Radiation can be useful to treat tumors on the eyelids, nose, ears, and lips when surgery is not practical. The disadvantages are the cost, blind margin control, and prolonged treatment duration. The cure rate for tumors larger than 2 cm is 85% to 95%.¹²⁵ Radiation therapy is best avoided in treating verrucous carcinomas and younger patients because of poor long-term cosmetic results. SCCs that have arisen from ulcers, scars, and irradiated sites are better removed by margin-controlled surgery than by radiation therapy.

Treatment of Locally Advanced and Metastatic Disease

Aggressive or deeply invasive SCCs are treated with deep surgical excision with margin control when practical. Mohs surgery may be helpful in delineating critical areas in massive tumors or tumors with ill-defined borders. SCC invading surrounding structures such as bone and cartilage must also be excised. Tumors with neural or perineural involvement that are at high risk of recurrence should be completely excised preferably with the Mohs technique. High-risk tumors may require adjuvant therapy with radiation therapy¹²⁶ or chemotherapy.^127,128

A recent review article summarized treatment modalities for locally advanced nonmetastatic cutaneous SCC.¹²⁹ Commonly used traditional chemotherapy includes oral capecitabine and intravenous platinum-based regimens. Biological response modifiers refer to agents that augment host antitumor immune responses, examples of which include oral isotretinoin and interferons. Because in vitro studies demonstrated synergism between retinoids and interferons, these agents have been used in combination with success.^130,131 Newer targeted agents are promising, including epidermal growth factor receptor antagonists, small-molecule tyrosine kinase inhibitors, and proteasome inhibitors.

Sentinel lymph node biopsy may be considered in patients with high-risk SCC.132,133 If lymph node metastasis has occurred, treatment is wide surgical resection of tumor with regional lymph node dissection with or without adjunctive radiation. However, elective lymph node dissection is not commonly performed in the absence of evidence for regional spread.

Epidemiology

Although most cases of KA are solitary, subsets of individuals with multiple KAs have been described. These include the familial Ferguson-Smith type, comprising multiple KAs at an early age, and the generalized eruption of thousands of small KAs as described by Grzybowski.¹³⁶ KAs frequently occur in individuals with MTS, XP, and solid-organ transplantation.¹³⁷ They also occur in areas of scarring from prior trauma, thermal burns, and surgical treatment, and in association with many benign conditions such as stasis dermatitis, lichen planus, lichen simplex chronicus, psoriasis, and discoid lupus erythematosus.¹³⁴

Etiology and Biological Characteristics

Debate exists as to whether KAs are a distinct clinical entity or a subtype of well-differentiated SCC. Significant efforts have been made to find practical, reliable criteria to distinguish KA from SCC.138,139 Similarities include expression of oncogenetic and cell cycle–regulating proteins including p53; a subset of these tumors also share trisomy 7 anomaly.^140–143 On the other hand, studies on apoptotic marker P2X₇, on antiapoptotic Bcl-xL protein, on loss of heterozygosity, on expression of angiotensin type 1 receptor and of desmogleins 1 and 2, on adhesion molecules vascular cellular adhesion molecule and intercellular adhesion molecule, on telomerase activity, and on chromosomal aberrations assessed by comparative genomic hybridization suggest that KA and SCC possess distinct genetic aberrations that result in separate developmental pathways.^144–152 One study localized recurrent aberrations to chromosomes 17, 19, 20, and X in one-third of the KAs studied. Recurrent aberrations on chromosomes 7, 8, 10, and 13 were characteristic of SCC, not of KA, perhaps accounting for the progressive growth and lack of regression of SCC.¹⁵³ Microsatellite instability and loss of heterozygosity are seen uncommonly in KA unless associated with MTS.

Prevention and Early Detection

Because UV exposure is a key component of etiology, sun-protective clothing, sunblock use, and avoidance of UV exposure are the primary means of prevention. Timely diagnosis and appropriate treatment of chronic scarring conditions could reduce incidence in the affected population. Self skin-examination or examination by a dermatologist to identify the characteristic lesion is the only means of early detection.¹³⁵

Pathology and Pathways of Spread

Histologically, a mature KA has a distinctive architecture characterized by a keratin-filled crater lined by a proliferating squamous epithelium with abundant pale eosinophilic “glassy” cytoplasm, epithelial lipping, and multiple keratin horn pearls with central orthokeratosis. Cytology is often indistinguishable from that of a well-differentiated cystic SCC. At the base of the tumor, islands and strands of atypical cells may invade the dermis. Frequently there is a heavy inflammatory infiltrate at the base of the lesion comprising lymphocytes, plasma cells, neutrophils, and eosinophils. Atypical mitoses, as well as perineural and perivascular invasion, also may be present, particularly in tumors involving the head and neck.154,155

Clinical Manifestations/Patient Evaluation/Staging

Patients will usually describe rapid onset and growth of a firm nodule with central depression filled with keratinous crustlike material over sun-exposed sites. The lesion will involute spontaneously leaving an atrophic scar over the course of several weeks. If evaluated early, a biopsy extending into the dermis is warranted to secure the diagnosis and to assess for SCC. Palpation of regional lymph nodes is indicated if there is suspicion for SCC, a cutaneous carcinoma known to metastasize.¹³⁴

Primary Therapy

Although not thought to metastasize in general, several cases of highly aggressive and metastatic KAs have been reported, leaving some to question whether these were truly KAs or rather KA-like SCCs.¹³⁶ However, given reported cases of local destruction and metastatic disease, it is recommended that KAs be treated in the same manner as SCCs. Complete conservative excision or Mohs micrographic surgery is the mainstay of therapy.¹⁵⁶ Radiotherapy, photodynamic therapy, electrodessication and curettage, systemic immunosuppressive medications, systemic retinoids, and topical and intralesional immunosuppressive and immunomodulating modalities have been reported with varying success.^157–163

Future Possibilities and Clinical Trials

Further elucidating the genetic differences between KA and SCC may help distinguish divergences in the biological behavior of these neoplasms. Such data can refine diagnostic and therapeutic efforts in the future.

Epidemiology

Reports on the incidence of NMSC varies in organ transplant populations studied from different parts of the world and also varies with the specific transplanted organ. Within 10 years from solid organ transplantation, 15% to 43% of recipients will develop NMSC. The highest risk is associated with heart and lung transplantation, the next with kidney transplantation, and the least with liver transplantation.¹⁶⁴ This corresponds to the overall degree of immunosuppression required to prevent rejection of the specific organ in each population. The most significant risk factors for the development of NMSC in organ transplant recipients include advanced age, cumulative UV exposure pretransplantation, degree and duration of immunosuppression, fair skin type, diagnosis of NMSC prior to transplantation, pretransplantation disease requiring prior immunosuppression (e.g., systemic lupus), and diagnosis of lymphoma before or after transplantation.^99,165

In addition to the organ transplant population, there is mounting evidence for concern regarding increased risk of NMSC in other immunosuppressed populations. There is significantly increased risk for patients with rheumatologic disease and psoriasis receiving tumor necrosis factor inhibitors, methotrexate and prednisone.166,167 Immune dysregulation from chronic lymphocytic leukemia elevates risk of aggressive SCC and subsequent mortality.¹⁶⁸ Highly active antiretroviral therapy has dramatically increased the longevity of the HIV-infected populations and with that has evolved a significant increase in BCCs and SCCs.¹⁶⁹ The use of thiopurines to treat inflammatory bowel disease has been shown to substantially increase the risk of SCC development.¹⁷⁰

Prevention and Early Detection

Appropriate dermatologic care for organ transplant recipients (and presumably others with significant chronic immunosuppression, although these guidelines are less-well established) should be based on risk stratification. All individuals should receive baseline screening and risk assessment by a dermatologist and education regarding skin cancer risk, photoprotection, and self-screening. Many transplantation centers have dermatologists with specific expertise in the care of these patients. Those determined to be at increased risk should be screened every 6 to 12 months, or more frequently if they develop multiple or aggressive skin cancers.⁹⁹

Pathology and Pathways of Spread

Please see specific sections of this chapter for each tumor type.

Clinical Manifestations/Patient Evaluation/Staging

Please see specific sections of this chapter for each tumor type.

Primary Therapy

Treatment of NMSC in organ transplant recipients and similarly immunosuppressed patients should be tailored to the individual’s needs. Standard modalities, including excision, electrodessication and curettage, curettage and cryotherapy, and Mohs micrographic surgery, are appropriate in most cases. Aggressive treatment of precancerous lesions with standard modalities, such as cryotherapy, topical retinoids, imiquimod, topical 5-fluorouracil, and photodynamic therapy, is beneficial. Patients with extensive photodamage amounting to areas of “field cancerization” should be identified and treated aggressively with standard modalities, then monitored closely to reduce the risk of developing numerous or aggressive tumors in these areas.¹⁰⁰

Locally Advanced Disease and Palliation

Organ transplant recipients developing multiple new primary skin cancers (5 to 10 per year) or skin cancers with aggressive histologic subtypes despite appropriate monitoring and therapy are candidates for chemopreventive therapy. Acitretin can be used at doses from 10 to 25 mg daily with significant reduction in the number of new NMSC for many patients. Dosage is limited by side effects. Liver function, kidney function, and blood lipids must be monitored while on therapy. The chemopreventive effect of acitretin lasts only for the duration of therapy, and a rebound of SCC may occur upon discontinuation of acitretin.99,100

Revision of immunosuppression may be appropriate for patients who develop multiple or histologically aggressive NMSC. Consultation should take place between the patient and the patient’s transplant physicians regarding possible reduction of current medication or a switch to a comparable immunosuppressive agent with a better side-effect profile for skin cancer. When graft function is stable and surgical wounds have healed, sirolimus or everolimus may be considered for their antineoplastic properties. Sirolimus is associated with a significant reduction in malignancies posttransplantation. Azathioprine should be discontinued if possible because of its photocarcinogenic properties. Tacrolimus is preferable to cyclosporine as a first-line calcineurin inhibitor because of an associated lower risk of NMSC. Although triple-drug immunosuppressive therapy remains the standard treatment after organ transplantation at most centers, dual therapy and calcineurin inhibitor monotherapy have been shown to reduce NMSC without significant increase in organ rejection in patients more than 6 years posttransplantation.¹⁶⁵

Treatment of Metastatic Disease

Patients with aggressive, large, recurrent, numerous or metastatic NMSC should be referred to a provider with expertise in the evaluation of their metastatic potential and management. A role for sentinel lymph node biopsy has been established in select aggressive SCC. Adjuvant radiation therapy is helpful in selected cases of SCC or BCC that are aggressive or have high-risk features. Involvement of a multidisciplinary transplant team that includes transplant physicians, dermatologists, oncologists, radiation oncologists, otorhinolaryngologists, and plastic surgeons, may benefit those patients who are extensively afflicted with NMSC.¹⁶⁵

Future Possibilities and Clinical Trials

Current efforts to improve outcomes for organ transplant recipients with nonmelanoma skin cancers are centered on modification of current immunosuppressive regimens and adaptation of immunosuppressive regimens using newer agents with more favorable side-effect profiles regarding skin cancer development, such as sirolimus and everolimus. Transplantation centers continue to investigate regimens that minimize immunosuppression at induction and later in the course of transplantation for appropriate patient candidates. For example, calcineurin monotherapy (compared to two- or three-agent regimens) was associated with a higher graft survival rate and a lower skin cancer rate in selected patients 6 to 12 years posttransplantation.¹⁷¹ Ongoing studies are needed to further understand appropriate strategies for optimization of graft survival weighed against the risk of carcinogenesis.

Epidemiology

OSC accounts for 0.2% to 0.8% of all eyelid tumors and 1% to 1.5% of all malignant tumors of the eyelid.¹⁷⁴ OSC affects women 1.5 times more frequently than men; however, a slight male preponderance occurs in cases of ESC.^175–179 The mean age at diagnosis is 65 years (range: 40 to 60 years), but OSC has been reported in adults in their nineties and in a 3-year-old child. Sebaceous carcinoma seems to have a higher incidence in the Asian population.^180–183

Etiology and Biological Characteristics

This tumor is associated with MTS, an autosomal-dominant disorder of mismatch repair genes characterized by sebaceous tumors (benign and malignant), as well as other visceral malignant tumors.¹⁸⁴ Although sebaceous carcinoma with microsatellite instability has been found in several renal organ transplant recipients,¹⁸⁴ only a subset of these tumors possess microsatellite instability. Mutations in p53 are significantly associated with sebaceous carcinoma and are independent of microsatellite instability, therefore suggesting a divergence in molecular pathogenesis.¹⁸⁵ Epigenetic inactivation of E-cadherin, leading to loss of the membrane bound molecule, is associated with reduced disease-free survival in OSC.¹⁸⁶

There is evidence that the chronic inflammation caused by chalazion may be causative in OSC. The unsaturated 8-carbon fatty acid oleic acid has been shown to cause dysplasia in glandular structures.¹⁷²

Risk factors associated with poor prognosis include duration longer than 6 months; vascular or lymphatic involvement; orbital extension; poorly differentiated tumor morphology; multicentricity; pagetoid spread into the conjunctival epithelium, cornea, or skin; upper and lower lid involvement; and history of radiation exposure.180,187–189 In the past, 14% to 25% of patients reportedly had metastasis, most frequently involving regional nodal basins, followed by spread to the liver, lung, brain, and bones.^{175,177–180}

Related posts:

Hematopoietic Stem Cell Transplantation Cancer Immunology Acute Abdomen, Bowel/Biliary Obstruction, and Fistula Childhood Lymphoma Neurologic Complications Eye, Orbit, and Adnexal Structures

Stay updated, free articles. Join our Telegram channel

Join